| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |